Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
LMTK3 inhibitor C28 is a multi-kinase inhibitor.1 It inhibits lemur tyrosine kinase 3 (LMTK3), CDC-like kinase 2 (Clk2), dual-specificity tyrosine phosphorylation-regulated kinase 1α (DYRK1α), homeodomain-interacting protein kinase 2 (HIPK2), and IL-1 receptor-associated kinase 4 (IRAK4; IC50s = 67, 5, 6, 48, and 41 nM, respectively), among others. LMTK3 inhibitor C28 is selective for these kinases over a panel of 122 kinases at 1 µM. It induces proteasomal degradation of LMTK3 in MCF-7, T47D, and MDA-MB-231 breast cancer cells when used at concentrations of 5 or 10 µM. LMTK3 inhibitor C28 (10 µM) reduces the levels of IRAK4, estrogen receptor α (ERα), phosphorylated tropomyosin-related kinase A (TrkA), and HIPK2 in T47D cells. It induces induces apoptosis in MCF-7, T47D, and MDA-MB-231 cells when used at a concentration of 10 µM. In vivo, LMTK3 inhibitor C28 (10 mg/kg per day) reduces tumor growth and volume in an MDA-MB-231 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. The structure-